Reversible BTK Inhibitor Data for Neuroinflammation Therapeutics

Brian T. Hopkins published a dataset on April 7, 2026, detailing the discovery of selective, CNS-penetrant reversible Bruton's Tyrosine Kinase inhibitors for treating neuroinflammation. The dataset is small, at 3.9 KB, and focuses on molecular design and safety considerations for potential therapeutics in conditions like multiple sclerosis.

Use Cases

• Analyze molecular properties of reversible BTK inhibitors designed to target the Tyr-551 phosphorylation site.
• Compare safety profiles and CNS exposure levels of different inhibitor candidates.
• Investigate the relationship between B-cell receptor signaling blockade and potential microglial toxicity.

Strengths

• Data is recent, published in April 2026.
• Focuses on a specific, clinically relevant target (Bruton's Tyrosine Kinase) for neuroinflammation.

Limitations

• Dataset is very small at 3.9 KB, indicating limited scope and likely a small number of records.
• No column names or sample data are provided, making structure and content analysis difficult.
• License is CC-BY-NC-4.0, restricting commercial use.

Provenance

Source

Brian T. Hopkins via figshare.

Freshness

Last updated on 2026-04-07.